LXRX insider transaction filings
LEXICON PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-04. Screen LXRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-04 | 4 | Swain Judith L — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Sullivan Diane E. — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Cheung Ivan — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | BARKER SAM L — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Amouyal Philippe — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | SOBECKI CHRISTOPHER J — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | DEBBANE RAYMOND — Director | Option exercise (M): 89,312 @ $0 · Option exercise (M): 89,312 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Artal Participations S.a r.l. — Director, 10% owner Artal International S.C.A. — Director, 10% owner Artal International Management S.A. — Director, 10% owner Artal Group S.A. — Director, 10% owner Westend S.A. — Director, 10% owner Stichting Administratiekantoor Westend — Director, 10% owner Wittouck Amaury — Director, 10% owner | Option exercise (M): 20,421,735 @ $0 · Grant/award (A): 408,434.70 (derivative) · Option exercise (M): 408,434.70 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Amouyal Philippe — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | BARKER SAM L — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Cheung Ivan — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Swain Judith L — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Sullivan Diane E. — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | SOBECKI CHRISTOPHER J — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | DEBBANE RAYMOND — Director | Grant/award (A): 35,714 (derivative) @ $0 · Grant/award (A): 43,478 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | McDermott Wendy — SVP, Human Resources | Option exercise (M): 27,697 · Option exercise (M): 52,316 · Option exercise (M): 144,393 · Tax withholding (F): 68,107 @ $1.47 · Option exercise (M): 27,697 (derivative) · Option exercise (M): 52,316 (derivative) · +1 more | EDGAR |
| 2026-03-03 | 4 | Martens Rachel Yap — SVP, Partnerships & Corp Strat | Option exercise (M): 67,090 · Tax withholding (F): 35,826 @ $1.47 · Option exercise (M): 67,090 (derivative) | EDGAR |
| 2026-03-03 | 4 | Granowitz Craig B — SVP, Chief Medical Officer | Option exercise (M): 35,790 · Option exercise (M): 74,226 · Option exercise (M): 202,260 · Tax withholding (F): 109,098 @ $1.47 · Option exercise (M): 35,790 (derivative) · Option exercise (M): 74,226 (derivative) · +1 more | EDGAR |
| 2026-03-03 | 4 | Gopinathan Suma — SVP, Discovery | Option exercise (M): 14,000 · Option exercise (M): 20,310 · Option exercise (M): 65,640 · Tax withholding (F): 24,338 @ $1.47 · Option exercise (M): 14,000 (derivative) · Option exercise (M): 20,310 (derivative) · +1 more | EDGAR |
| 2026-03-03 | 4 | DeFrancesco Lisa — SVP, IR and Corp Comm | Option exercise (M): 24,674 · Option exercise (M): 128,190 · Tax withholding (F): 74,572 @ $1.47 · Option exercise (M): 24,674 (derivative) · Option exercise (M): 128,190 (derivative) | EDGAR |
| 2026-03-03 | 4 | Crum Brian T — SVP, General Counsel & Secr. | Option exercise (M): 33,457 · Option exercise (M): 69,386 · Option exercise (M): 170,163 · Tax withholding (F): 105,019 @ $1.47 · Option exercise (M): 69,386 (derivative) · Option exercise (M): 33,457 (derivative) · +1 more | EDGAR |
| 2026-03-03 | 4 | Coiante Scott M — SVP, Chief Financial Officer | Option exercise (M): 160,237 · Tax withholding (F): 54,881 @ $1.47 · Option exercise (M): 160,237 (derivative) | EDGAR |
| 2026-03-03 | 4 | Exton Michael — Chief Executive Officer, Director | Option exercise (M): 503,263 · Tax withholding (F): 204,831 @ $1.47 · Option exercise (M): 503,263 (derivative) | EDGAR |
| 2026-02-27 | 4 | DEBBANE RAYMOND — Director | Purchase (P): 2,000 @ $1.49 | EDGAR |
| 2026-02-25 | 4 | DEBBANE RAYMOND — Director | Purchase (P): 100,000 @ $1.47 | EDGAR |
| 2026-02-23 | 4 | DEBBANE RAYMOND — Director | Purchase (P): 50,000 @ $1.44 · Purchase (P): 100,000 @ $1.48 | EDGAR |
| 2026-02-19 | 4 | Artal Participations S.a r.l. — Director, 10% owner Artal International S.C.A. — Director, 10% owner Artal International Management S.A. — Director, 10% owner Artal Group S.A. — Director, 10% owner Westend S.A. — Director, 10% owner Stichting Administratiekantoor Westend — Director, 10% owner Wittouck Amaury — Director, 10% owner | Grant/award (A): 41,289.58 @ $65 | EDGAR |
| 2026-02-18 | 4 | DEBBANE RAYMOND — Director | Purchase (P): 57,952 @ $1.31 · Purchase (P): 76,857 @ $1.31 · Purchase (P): 133,688 @ $1.32 | EDGAR |
| 2026-02-17 | 4 | McDermott Wendy — SVP, Human Resources | Grant/award (A): 250,200 (derivative) @ $0 · Grant/award (A): 375,300 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Martens Rachel Yap — SVP, Partnerships & Corp Strat | Grant/award (A): 193,740 (derivative) @ $0 · Grant/award (A): 290,620 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Granowitz Craig B — SVP, Chief Medical Officer | Grant/award (A): 346,610 (derivative) @ $0 · Grant/award (A): 519,920 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Gopinathan Suma — SVP, Discovery | Grant/award (A): 238,450 (derivative) @ $0 · Grant/award (A): 357,680 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | DeFrancesco Lisa — SVP, IR and Corp Comm | Grant/award (A): 257,530 (derivative) @ $0 · Grant/award (A): 386,300 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Crum Brian T — SVP, General Counsel & Secr. | Grant/award (A): 299,710 (derivative) @ $0 · Grant/award (A): 449,560 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Coiante Scott M — SVP, Chief Financial Officer | Grant/award (A): 272,680 (derivative) @ $0 · Grant/award (A): 409,020 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Exton Michael — Chief Executive Officer, Director | Grant/award (A): 862,440 (derivative) @ $0 · Grant/award (A): 1,293,670 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Invus Global Management, LLC — Director, 10% owner Siren, L.L.C. — Director, 10% owner DEBBANE RAYMOND — Director Artal Participations S.a r.l. — Director, 10% owner Artal International S.C.A. — Director, 10% owner Artal International Management S.A. — Director, 10% owner Artal Group S.A. — Director, 10% owner Westend S.A. — Director, 10% owner Stichting Administratiekantoor Westend — Director, 10% owner | Grant/award (A): 18,553,846 @ $1.30 · Grant/award (A): 3,846,154 @ $1.30 · Purchase (P): 1,538,462 @ $1.30 · Grant/award (A): 367,145.12 @ $65 | EDGAR |
| 2025-06-03 | 4 | Swain Judith L — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Sullivan Diane E. — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Cheung Ivan — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | BARKER SAM L — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Amouyal Philippe — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | SOBECKI CHRISTOPHER J — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | DEBBANE RAYMOND — Director | Grant/award (A): 103,806 (derivative) @ $0 · Grant/award (A): 89,312 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Swain Judith L — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Sullivan Diane E. — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | BARKER SAM L — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | Amouyal Philippe — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | SOBECKI CHRISTOPHER J — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4 | DEBBANE RAYMOND — Director | Option exercise (M): 36,810 @ $0 · Option exercise (M): 36,810 (derivative) @ $0 | EDGAR |
Recent 8-K events — LEXICON PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-29 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LXRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →